Viemed Healthcare, Inc.

NASDAQ:VMD

Medical - Devices

Healthcare
$8.61 +0.68%

+$0.07 today

Market cap
$326.26M
Beta
1.13
P/E (TTM)
27.4
EPS (TTM)
$0.39
52W Low $5.93High $10.68

Volume 0.17M

Average 0.26M

Financial health

Viemed Healthcare, Inc. financial health

Start with the overall verdict and the rule-based risk checks for VMD, then work through liquidity, debt, balance-sheet quality, and claims on cash.

Financial health snapshot

Resilient

Debt service and balance sheet cushion look healthy, even if some working-capital ratios deserve context.

Cash and investments cover debt Healthy short-term liquidity Moderate leverage Interest well covered

Cash & Investments

$12.56M

Debt Cushion

$119,000.00

Current Ratio

1.2x

Interest Coverage

15.5x

Risk checks

1 of 11 checks flagged

  • Debt growth versus revenue growth

    184.3% vs. 24.9%

    Passes when: Over three years, debt growth is no more than 5 percentage points above revenue growth.

  • Positive equity

    Positive

    Passes when: Shareholders’ equity is above zero.

  • Interest coverage

    18.4×

    Passes when: Operating income is at least 1.5 times interest expense.

  • Short-term liquidity

    1.2×

    Passes when: Current assets are at least 1 times current liabilities.

  • Near-term debt coverage

    11.2×

    Passes when: Cash and short-term investments cover debt due within 12 months.

  • Manageable net debt

    0.1×

    Passes when: Net debt is below 3 times EBITDA.

  • Debt repayment from cash flow

    0.5 yr

    Passes when: Free cash flow could repay all debt within 5 years.

  • Tangible equity base

    41.8%

    Passes when: Goodwill and intangibles are below 50% of equity.

  • Altman Z-score trend

    6.68 → 4.71

    Passes when: The Z-score is stable or rising, or stays above 2.99.

  • Stock-based compensation

    16.2%

    Passes when: Stock-based compensation is no more than 20% of operating cash flow.

  • Share dilution

    +0.1% per year

    Passes when: Diluted share count grows no more than 2% per year.

Financial strength scores

How strong are the fundamentals over time?

Piotroski tests profitability, balance-sheet direction, and efficiency; Altman estimates bankruptcy risk. Compare the current scores with their fiscal-year history.

Financial strength scores

Piotroski F-Score and Altman Z-Score from the latest reported financials

Piotroski F-Score

Strong

8 / 9

Nine pass/fail tests of profitability, balance-sheet strength, and efficiency. 8–9 is strong, 0–3 is weak.

Altman Z-Score

Safe zone

6.42

Bankruptcy-risk model. Above 2.99 is the safe zone, 1.81–2.99 the grey zone, and below 1.81 the distress zone.

Score history

Piotroski F-Score and Altman Z-Score recalculated from each fiscal year's statements and year-end market value.

Piotroski: 8–9 strong, 4–7 average, 0–3 weak. Altman: above 2.99 safe, 1.81–2.99 grey, below 1.81 distress. Our calculation can differ slightly from the provider's current scores above.

Liquidity

Can it meet short-term obligations?

Check whether cash and current assets cover what falls due within a year without depending on fresh financing.

Cash & Equivalents

$9.76M

Q1 2026

3Y -21.3%1Y -27.7%

Quick Ratio

1.1x

Q1 2026

Current Ratio

1.2x

Q1 2026

Cash Ratio

0.2x

Q1 2026

Working capital

How quickly does cash come back?

Receivable, inventory, and payable days show how much cash the operating cycle ties up and whether that is changing.

Working capital and cash conversion

Annual days measures from year-end receivables, inventory, and payables against revenue and cost of revenue.

Working capital (Q1 2026)

$9.11M

Current assets − current liabilities

Days sales outstanding

35 d

-6 days vs. prior year

Days inventory outstanding

16 d

-1 days vs. prior year

Days payables outstanding

39 d

+2 days vs. prior year

Cash conversion cycle

11 d

-9 days vs. prior year

Leverage

How much debt risk sits on the balance sheet?

Review total borrowings, debt relative to equity and assets, and whether operating profit covers interest costs.

Total Debt

$12.44M

Q1 2026

3Y +21.8%1Y -22.0%

Debt/Equity

0.1x

Q1 2026

Debt/Assets

0.1x

Q1 2026

Interest Coverage

15.5x

Q1 2026

Debt service

Can cash flow carry the debt?

Measure debt against EBITDA and free cash flow, see how much is due within 12 months, and follow debt and cash over time.

Debt service capacity

Can operating cash flow carry the debt, and how much is due soon?

Net debt

$2.68M

Total debt − cash − short-term investments

Net debt / EBITDA

0.1×

Above 3× is elevated

Free cash flow / debt

208.4%

Share of debt one year of FCF could repay

Years to repay debt

0.5 yr

Total debt ÷ free cash flow

Operating cash flow / current liabilities

1.4×

Above 1× funds a year of obligations

Interest coverage

18.4×

Operating income ÷ interest expense

Debt maturity

Cash and short-term investments cover short-term debt 11.2×.

Due within 12 months$871KDue later$8.33M

Balance sheet as of Q1 2026; cash flows TTM to Q1 2026.

Debt and cash over time

Fiscal-year-end borrowings against liquid assets; net debt below zero means net cash.

Balance sheet cushion

How much room is there if conditions weaken?

Extra cash and investments, and the balance of assets against liabilities, give the company room when trading gets harder.

Long-Term Investments

$2.79M

Q1 2026

3Y +0.0%1Y +0.0%

Assets

$197.36M

Q1 2026

3Y +2.3%1Y -8.2%

Liabilities

$51.56M

Q1 2026

3Y +6.3%1Y -27.8%

Balance sheet quality

Who funds the assets, and how tangible is the equity?

Split the claims on assets between suppliers, lenders, customers, and shareholders, and see how much equity rests on goodwill and intangibles.

Balance sheet quality

Who funds the assets, and how much of the equity is tangible (Q1 2026).

Claims on $197.36M in assets

  • Payables6.8%
  • Short-term debt0.4%
  • Long-term debt4.2%
  • Deferred revenue3.8%
  • Other liabilities10.9%
  • Equity73.9%

Goodwill + intangibles

$60.16M

30.5% of total assets

Share of equity

41.8%

Above 50% leaves little tangible backing

Tangible equity

$83.7M

Equity left after writing off goodwill and intangibles

Deferred revenue

$7.48M

Customer prepayments: a liability settled by delivering service, not cash

Shareholder claims

What do shareholders take out of the cash?

Dilution, stock-based pay, dividends, and buybacks all draw on cash flow; check whether free cash flow funds them.

Shareholder claims on cash

Dilution, stock-based pay, and whether free cash flow funds what is returned to shareholders.

Diluted shares, yearly change

+0.1%

Compound annual rate from FY 2020 to FY 2025

Stock-based compensation

$9.27M

16.2% of operating cash flow

Dividends paid

None

TTM to Q1 2026

Dividend / free cash flow

—

Above 100% means dividends exceed free cash flow

Buybacks

$14.77M

TTM to Q1 2026

Weighted diluted shares outstanding

Competitor health

How does Viemed Healthcare, Inc. compare with peers?

Compare leverage, interest coverage, and liquidity ratios with similar companies.

Competitor Health

Peer financial health comparison

CompanyMarket CapD/ED/AssetsND/EBITDAInt. Cov.QuickCurrentCash

Sight Sciences, Inc.

SGHT:NASDAQ

$601.92M0.640.351.56—9.5210.228.34

Senseonics Holdings, Inc.

SENS:NASDAQ

$579.58M0.680.33Net cash—4.554.831.67

908 Devices Inc.

MASS:NASDAQ

$405.01M0.120.093.33—3.864.243.32

Electromed, Inc.

ELMD:AMEX

$198.79M0.000.00Net cash—3.994.311.46

Inogen, Inc.

INGN:NASDAQ

$147.95M0.090.0631.71—2.713.121.63

Quanterix Corporation

QTRX:NASDAQ

$139.11M0.130.09Net cash—2.112.840.40

Outset Medical, Inc.

OM:NASDAQ

$70.32M0.800.38Net cash—5.406.670.93

Nano-X Imaging Ltd.

NNOX:NASDAQ

$25.36M0.060.050.84—3.773.962.91

CVRx, Inc.

CVRX:NASDAQ

$17.30M1.290.480.53—6.727.635.69

SANUWAVE Health Inc.

SNWV:NASDAQ

$15.66M14.190.620.570.791.051.380.67

Questions

Financial health questions

Common questions about VMD's balance sheet, answered from the reported figures.

Is VMD's balance sheet healthy?

Viemed Healthcare, Inc. (VMD) has a current ratio of 1.22, a quick read on short-term liquidity.

How leveraged is VMD?

Debt to equity is 0.09, which helps judge how much financing risk sits on the balance sheet.